Pacific Biosciences Of California (PACB) Non-Current Debt (2010 - 2023)

Pacific Biosciences Of California's Non-Current Debt history runs 13 years deep, the most recent figure standing at $500000.0 for Q4 2023.

• On a quarterly basis, Non-Current Debt fell 78.26% year-over-year to $500000.0 in Q4 2023; TTM through Dec 2023 was $500000.0, a 78.26% decrease from a year earlier, with the FY2023 full-year figure at $500000.0, down 78.26% from the prior year.
• Non-Current Debt eased to $500000.0 in Q4 2023 per PACB's latest filing, from $459.0 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $459.0 million in Q2 2023 and bottomed at $500000.0 in Q4 2023.
• The 4-year median for Non-Current Debt is $2.3 million (2021), against an average of $96.0 million.
• Across the five-year window, Non-Current Debt grew 7.78% in 2019 and plunged 78.26% in 2023, its largest moves.
• Year by year, Non-Current Debt stood at $15.8 million in 2019, then tumbled by 85.44% to $2.3 million in 2021, then changed by 0.0% to $2.3 million in 2022, then plunged by 78.26% to $500000.0 in 2023.
• Per Business Quant, the three latest PACB Non-Current Debt figures stand at $500000.0 (Q4 2023), $459.0 million (Q2 2023), and $2.3 million (Q4 2022).